In Brazil, researchers at the University of São Paulo (USP) and their collaborators have identified a promising target for developing new Chagas disease treatments. In laboratory tests, the group succeeded in interrupting the infection cycle of the Trypanosoma cruzi parasite by reducing the production of one of its proteins.